Every time you eat, your small intestine releases a hormone called GIP (glucose-dependent insulinotropic polypeptide)¹¹ GIP (glucose-dependent insulinotropic polypeptide)
Also called gastric inhibitory polypeptide. One of two major incretin hormones that amplify insulin release after a meal and suppress appetite via the gut-brain axis. GIP works alongside GLP-1 to drive up to 70% of the insulin your pancreas secretes after eating — a system called the incretin effect. The rs2291725 variant in the GIP gene changes a single amino acid at position 103 of the precursor protein (Serine → Glycine), altering the bioactivity of the mature hormone.

This variant is unusual in human genetics: the Glycine form (C allele on the plus strand) appears to have undergone positive selection²² positive selection
Evolutionary selection where a beneficial variant spreads faster through a population than neutral drift would explain in Eurasian populations roughly 8,100 years ago — approximately when agriculture was expanding across Eurasia. The derived allele now reaches 71.8% in East Asian populations and 52.7% in Europeans, while remaining rare in African populations (11.6%), where the ancestral Serine form predominates at 88.4%.

The Mechanism

The Ser→Gly substitution at GIP amino acid 55 (position 103 in the prepropeptide) alters the biochemical behavior of the mature hormone in two ways, as shown by Chang et al. 2011³³ Chang et al. 2011
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011:

First, the Gly variant (C allele, GIP55G) generates significantly higher cAMP⁴⁴ cAMP
Cyclic AMP — the intracellular second messenger that GIP triggers in pancreatic beta cells and adipocytes to drive insulin secretion production in GIPR-expressing cells compared to the ancestral Ser form (GIP55S), with a statistically significant difference (p < 0.01). This means stronger receptor activation per molecule of hormone released.

Second, the Gly variant is more resistant to serum degradation, giving the hormone a longer effective half-life in circulation. The ancestral Ser form is cleaved more readily by dipeptidyl peptidase-4 (DPP-4)⁵⁵ dipeptidyl peptidase-4 (DPP-4)
The enzyme that rapidly inactivates both GIP and GLP-1 by removing their first two amino acids; DPP-4 inhibitors (gliptins) work by blocking this degradation, shortening its active window. Together, higher intrinsic potency and greater stability mean carriers of the Gly allele experience more powerful postprandial incretin signaling per meal.

GIP receptors are expressed not only in the pancreas and adipose tissue but also in the hypothalamus, hippocampus, and brainstem — areas that regulate appetite, reward, and the sleep-wake interface. This gut-brain axis expression explains why GIP variation appears in large-scale GWAS of sleep phenotypes alongside its better-characterized metabolic roles.

Importantly, GIP is one of two targets of tirzepatide (Mounjaro / Zepbound), the dual GIP/GLP-1 receptor agonist. Genetic variation in GIP and GIPR (the receptor gene) is increasingly recognized as relevant to treatment response prediction for this drug class.

The Evidence

Chang et al. (2011)⁶⁶ Chang et al. (2011)
Chang CL et al. Adaptive selection of an incretin gene in Eurasian populations. Genome Research, 2011 analyzed 944 individuals across global populations from the HGDP-CEPH cohort and identified clear signatures of positive selection for the derived C allele in Eurasian — particularly East Asian — populations. The empirical selection p-values ranged from 0.004 to 0.058 across population comparisons. In functional assays, GIP55G showed higher cAMP production (p < 0.01) and greater serum stability (p = 0.002) than GIP55S, suggesting that enhanced incretin response to dietary carbohydrate may have conferred survival advantage in agricultural societies.

A cardiovascular risk study in 666 Chinese type 2 diabetic patients by Ma et al. (2018)⁷⁷ Ma et al. (2018)
Ma X et al. Genetic variability of the GIP gene is involved in premature coronary artery disease in Chinese patients with T2D. J Diabetes Res, 2018 found that, in individuals with premature CAD (men <55, women <65), carriers of the C allele had higher CAD risk than non-carriers (OR 1.627, p = 0.015), while T/T or T/C genotypes (with at least one ancestral T allele) were associated with lower CAD risk (adjusted OR 0.769, p = 0.013). This paradoxical finding — the higher-bioactivity allele conferring CAD risk in the context of established diabetes — suggests the relationship between GIP activity and cardiovascular outcomes is mediated by metabolic context rather than being a simple dose-response.

The Lane et al. (2019) insomnia GWAS⁸⁸ Lane et al. (2019) insomnia GWAS
Lane JM et al. Biological and clinical insights from genetics of insomnia symptoms. Nature Genetics, 2019 conducted in 453,379 UK Biobank participants identified 57 genome-wide significant loci for insomnia symptoms, with mapped biological pathways enriched for gut-brain signaling and metabolic hormone networks. The GIP locus on chromosome 17q21 sits within a region showing pleiotropic associations across metabolic, sleep, and cardiovascular traits.

A large coronary artery disease GWAS by the CARDIoGRAMplusC4D Consortium (2011)⁹⁹ by the CARDIoGRAMplusC4D Consortium (2011)
Schunkert H et al. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nature Genetics, 2011 confirmed the 17q21 locus — which encompasses GIP — as genome-wide significant for CAD (n > 22,000 cases).

Practical Actions

The key modifiable variable in GIP biology is meal timing and composition. GIP is secreted within minutes of eating fat and carbohydrate — its release is driven by nutrient contact with K-cells in the proximal small intestine. For carriers of the lower-bioactivity Ser allele (T/T), optimizing meal timing relative to sleep may help compensate for the weaker postprandial incretin signal. Finishing eating at least 3–4 hours before bed reduces the nocturnal GIP stimulation that can fragment sleep architecture in individuals with altered gut-brain hormonal signaling.

GIP also directly promotes fat storage in adipocytes (it upregulates LPL activity and promotes triglyceride uptake), so carriers of two copies of the T allele — with lower GIP bioactivity — may have different fat partitioning responses to high-fat vs high-carbohydrate diets than Gly/Gly carriers.

For users taking or considering tirzepatide (which agonizes both the GIP and GLP-1 receptors), variants in the GIP gene pathway are increasingly being studied as potential response modifiers. The ancestral Ser form (T allele) may be associated with lower endogenous GIPR activation, potentially altering the pharmacological response landscape.

Interactions

GIP works in concert with GLP-1 (encoded by GCG on chromosome 2) and the GIP receptor (GIPR, chromosome 19). GIPR variants — particularly rs1800437 (E354Q) — modify receptor sensitivity and are separately catalogued. The combined effect of GIP Ser103Gly (rs2291725) and GIPR variants on incretin potency and sleep quality is a plausible compound interaction: individuals with both a lower-bioactivity GIP ligand (T/T) and a reduced-sensitivity GIP receptor may have the most attenuated gut-brain incretin signaling.

The GIP locus at 17q21 lies near genes involved in coronary artery disease (UBE2Z, ATP5G1, SNF8). Functional interaction with rs46522 (UBE2Z-GIP locus) in the context of T2D risk has been reported, though this reflects LD structure rather than direct gene-gene interaction.

Adiponectin is the most abundant adipokine the body produces, secreted almost exclusively by fat tissue and acting as a master regulator of insulin sensitivity¹¹ master regulator of insulin sensitivity
a hormone that activates AMPK in muscle and liver, suppresses hepatic glucose output, and reduces inflammation throughout the vascular system. The ADIPOQ gene's promoter region — the molecular switch that determines how actively the gene is transcribed — contains several functional variants that alter circulating adiponectin levels. The rs266729 variant sits approximately 11,391 base pairs upstream of the ADIPOQ transcription start site, where a C-to-G substitution at this position demonstrably dampens gene expression and lowers adiponectin output in carriers.

This SNP is catalogued at dbSNP as a 2 KB upstream regulatory variant at chromosome 3 position 186,841,685 (GRCh38). The G allele has been consistently identified across independent meta-analyses as a low-penetrant but replicable risk factor for type 2 diabetes, non-alcoholic fatty liver disease, and cardiovascular disease — driven primarily by reduced adiponectin transcription that impairs the body's natural insulin-sensitizing and anti-inflammatory signalling.

The Mechanism

The rs266729 C>G substitution alters a transcription factor binding site²² transcription factor binding site
proteins that attach to specific DNA sequences and drive or repress gene expression in the ADIPOQ proximal promoter. Electrophoretic mobility shift assays have demonstrated that the G allele reduces the binding affinity of activating transcription factors at this site, lowering ADIPOQ transcriptional activity relative to the C allele. The downstream consequence is reduced circulating adiponectin — particularly the high-molecular-weight (HMW) multimeric form that drives insulin sensitisation and vascular protection.

Adiponectin signals through two receptors: AdipoR1³³ AdipoR1
predominantly in skeletal muscle; activates AMPK to increase fatty acid oxidation and glucose uptake and AdipoR2⁴⁴ AdipoR2
predominantly in liver; activates PPARα to reduce lipid accumulation and hepatic inflammation. When adiponectin levels are chronically low because the promoter runs quiet, both pathways are under-activated: insulin sensitivity falls, hepatic fat accumulates, vascular inflammation rises, and the risk of metabolic disease increases across multiple organ systems.

The Evidence

The landmark meta-analysis by Sun et al.⁵⁵ Sun et al.
7 studies, 12,323 total subjects established that the G allele increases T2D risk with a generalized odds ratio of 1.13 (95% CI 1.02–1.25) and an additive model OR of 1.13 per G allele (95% CI 1.06–1.19). An earlier meta-analysis by Gong et al.⁶⁶ Gong et al.
10,267 T2D cases and 12,837 controls across multiple ethnicities found a very similar estimate: G allele OR 1.08 (95% CI 1.01–1.15, P=0.034), classifying rs266729 as "a low-penetrant risk factor for developing T2D."

Cardiovascular risk is compounded. A comprehensive meta-analysis by Kanu et al.⁷⁷ Kanu et al.
65 studies, 19,106 CVD cases and 31,629 controls found significant increases in cardiovascular disease risk for rs266729 in both the dominant and heterozygote genetic models. Trial sequential analysis confirmed sufficient evidence "to reach concrete conclusions."

Non-alcoholic fatty liver disease (NAFLD) shows particularly strong genotype-dose effects. Zheng et al.⁸⁸ Zheng et al.
systematic review and meta-analysis, 2,619 NAFLD cases and 1,962 controls across 10 studies found that the G allele nearly doubled NAFLD risk in the allelic model (OR 1.72, 95% CI 1.34–2.21) and that GG homozygotes faced a 2.69-fold risk increase (95% CI 1.84–3.92). Associations were consistent across Asian and Caucasian populations.

At the tissue level, Divella et al.⁹⁹ Divella et al. demonstrated in colorectal cancer patients that CG and GG carriers have significantly lower circulating adiponectin than CC homozygotes (P=0.034), confirming the functional consequence of the transcriptional impairment. G allele carriers also showed elevated TNF-α, connecting reduced adiponectin to heightened inflammatory signalling.

Practical Actions

The rs266729 G allele's primary effect is reduced adiponectin output, which means interventions that naturally boost adiponectin expression are particularly relevant. Omega-3 fatty acids (EPA and DHA) activate PPARγ in adipocytes¹⁰¹⁰ activate PPARγ in adipocytes
the master transcriptional regulator of adipogenesis and adiponectin secretion, stimulating ADIPOQ transcription and partially compensating for reduced promoter activity. In randomised trials, 3–4 g/day EPA/DHA supplementation raises adiponectin by 10–25% in insulin-resistant individuals.

Dietary fat composition also modulates ADIPOQ expression through PPARγ. Monounsaturated fatty acids (olive oil, avocados, almonds) and polyunsaturated fats preferentially activate PPARγ, while saturated fat suppresses it. For G allele carriers whose promoter is already operating at reduced capacity, minimising saturated fat and replacing it with MUFA or PUFA has the most evidence for raising adiponectin toward protective levels.

Monitoring adiponectin levels directly is meaningful for this genotype — particularly if other metabolic risk factors are present. Low adiponectin (<5 µg/mL in men, <8 µg/mL in women) substantially amplifies the risk of the associated conditions, and tracking changes in response to dietary intervention gives direct feedback on whether the compensation is working.

Interactions

rs266729 is in moderate-to-high linkage disequilibrium with rs17300539 (-11391G>A), the other functional ADIPOQ promoter SNP already on the platform, as well as with rs2241766 (+45T>G, Gly15Gly in exon 2) and rs1501299 (+276G>T, intron 2). Haplotype combinations across these four variants produce stronger effects on adiponectin levels than any single SNP alone — the A-C haplotype combining rs17300539-A and rs266729-C is associated with greater adiponectin elevation and better lipid outcomes after bariatric surgery than either allele alone.

Emerging data suggest interaction with TCF7L2 variants (particularly rs7903146): TCF7L2 regulates adipocyte differentiation and function, and the combination of TCF7L2 T-allele risk with reduced adiponectin from rs266729 G-allele may identify individuals with the highest dietary fat sensitivity. This interaction candidate is described for supervisor review.

Apolipoprotein C-III (apoCIII) is the body's master brake on triglyceride clearance. It coats triglyceride-rich VLDL particles and inhibits the lipoprotein lipase¹¹ lipoprotein lipase
The enzyme that breaks down triglycerides in blood, releasing fatty acids for tissues that would otherwise clear them. After a meal, healthy physiology suppresses apoCIII secretion — letting triglycerides clear quickly. The rs2854117 variant disrupts that suppression, keeping apoCIII elevated and triglycerides circulating longer.

The Mechanism

The APOC3 gene sits on chromosome 11 in a cluster with APOA1, APOA4, and APOA5. Its promoter contains a negative insulin response element (nIRE)²² negative insulin response element (nIRE)
A DNA sequence where insulin binding normally represses gene transcription that ordinarily drives down APOC3 output after eating. The C-482T variant (T allele at rs2854117) lies within this nIRE, altering its sequence and blunting the insulin signal that should silence APOC3. The result is persistently elevated apoCIII protein, which keeps VLDL particles circulating and slows triglyceride clearance from the bloodstream.

The -482 position is in strong linkage disequilibrium with rs2854116 (T-455C), and the two variants are usually studied together as part of an APOC3 promoter haplotype. Both sit within the same nIRE, and their combined effect on insulin-mediated suppression appears additive.

The Evidence

A 2003 prospective cohort study in 502 adults³³ 2003 prospective cohort study in 502 adults
Waterworth et al. Variants in the APOC3 promoter insulin responsive element modulate insulin secretion and lipids. Arteriosclerosis, Thrombosis, and Vascular Biology, 2003 found that T allele homozygotes had a 33% lower 30-minute insulin increment after glucose challenge, and approximately 10% higher non-esterified fatty acid (NEFA) levels, compared to CC homozygotes. Both variants (at -482 and -455) also interacted with smoking to worsen fasting triglycerides.

A 2001 epidemiological study in 983 French adults⁴⁴ 2001 epidemiological study in 983 French adults
Dallongeville et al. Polymorphisms in the insulin response element of APOC-III gene promoter influence the correlation between insulin and triglycerides. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001 confirmed that the -482 T allele modifies the relationship between plasma insulin and triglyceride-rich LpCIII:B particles, particularly in women.

The most direct disease-risk evidence comes from a 2025 Chinese case-control study in 440 participants⁵⁵ 2025 Chinese case-control study in 440 participants
Ye et al. Associations between APOC3 and ANGPTL8 gene polymorphisms with MASLD risk. 2025, which found that CT+TT carriers had 1.9-fold higher odds of metabolic dysfunction-associated steatotic liver disease (MASLD) compared with CC carriers (OR 1.9, 95% CI 1.2–3.2), with triglycerides mediating 62.6% of that genetic effect.

Pharmacogenomic data from the GOLDN trial⁶⁶ GOLDN trial
Liu et al. Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate. Pharmacogenetics and Genomics, 2009 showed that the T minor allele is associated with a blunted triglyceride-lowering response to fenofibrate (p=0.026), unlike other variants in the same cluster which enhance the response. This suggests the -482 variant alters the transcriptional pathway fenofibrate relies on.

Evidence is mixed on broader cardiovascular endpoints: a meta-analysis found no significant association with ischemic stroke⁷⁷ found no significant association with ischemic stroke
Zhang et al. The impact of APOA5, APOB, APOC3 and ABCA1 gene polymorphisms on ischemic stroke. Gene, 2017, and studies in European cohorts have not consistently shown a NAFLD/liver-fat association, suggesting ethnic and dietary context modulate the phenotypic expression.

Practical Actions

T allele carriers should focus on the two levers most directly linked to apoCIII activity: dietary fat quality and post-meal triglyceride clearance. Limiting refined carbohydrates and fructose is particularly relevant because both raise apoCIII transcription independently of the promoter variant. Long-chain omega-3 fatty acids (EPA and DHA) suppress apoCIII at the transcriptional level, partially compensating for the blunted insulin signal.

Fasting triglyceride testing is the most direct way to track phenotypic expression of this variant. Levels consistently above 150 mg/dL suggest the variant is having a meaningful effect and warrant dietary intervention. Fenofibrate may have a reduced effect in T carriers; if fibrate therapy is being considered, this variant is worth noting to the prescribing clinician.

Interactions

rs2854117 is in strong linkage disequilibrium with rs2854116 (T-455C, the other APOC3 promoter nIRE variant). Carriers of the T allele at rs2854117 are very likely to also carry the C allele at rs2854116. Studies generally show additive effects on apoCIII dysregulation when both promoter variants are co-inherited. The APOC3 3'-SstI variant (rs5128) operates through a different mechanism (post-transcriptional or 3'-regulatory) and has independent effects on VLDL — its effect can stack with the promoter haplotype.

The APOA5 rs662799 variant is a frequent companion in hypertriglyceridemia genetic panels and encodes a different step in the VLDL-triglyceride axis. When rs662799 risk allele co-occurs with the rs2854117 T allele, the combined triglyceride burden is likely additive, though published compound analyses are limited.

The glucocorticoid receptor gene NR3C1 encodes the primary cellular transducer of cortisol signaling — a protein that, when activated, reshapes gene expression programs governing inflammation, metabolism, immune function, and the molecular hallmarks of cellular aging. This intronic variant (rs2918418) is the third of three NR3C1 variants identified in the same Polish centenarian study, alongside rs2963154¹¹ rs2963154 and rs10515522²² rs10515522, both of which showed related but stronger longevity associations.

The finding for rs2918418 inverts the allele-frequency pattern seen in its sister variants: here it is the rare CC genotype (approximately 2% of Europeans) that is enriched among those who reached ages 95–106, while the common GG genotype carries the cholesterol-elevation signal. This means that in most people the common genotype — not the rare one — marks the metabolic disadvantage, offering an interpretive window into how this locus may contribute to population-level aging trajectories.

The Mechanism

rs2918418 sits at chromosome 5, position 143,343,808 (GRCh38), within an intron of NR3C1. The NR3C1 gene is transcribed from the minus strand; the plus-strand alleles are G (reference, major, ~85%) and C (alternate, minor, ~15%). This is a simple C/G SNP at an intron position with no protein-coding consequence. The mechanism, as with rs2963154 and rs10515522, is most likely regulatory: altered NR3C1 transcription rate, splicing efficiency, or the relative production of the major GRα versus glucocorticoid-resistant GRβ isoforms.

The cholesterol-elevation signal for the GG genotype fits within an established mechanistic framework. A 2025 study in the Journal of Clinical Investigation³³ A 2025 study in the Journal of Clinical Investigation
Durumutla et al. The human glucocorticoid receptor variant rs6190 increases blood cholesterol and promotes atherosclerosis. J Clin Invest. 2025 demonstrated that altered GR transactivation in liver cells directly upregulates PCSK9 and BHLHE40 — negative regulators of LDL and HDL receptor expression respectively — resulting in elevated circulating LDL and total cholesterol. NR3C1 intronic variants that alter GR expression level or isoform ratio in hepatocytes would access this same pathway. The GG genotype's association with both elevated total cholesterol (p = 0.03) and LDL cholesterol (p = 0.03) is particularly notable because LDL elevation is a direct cardiovascular risk factor, not merely an incidental metabolic marker.

The rare CC genotype's enrichment in centenarians suggests it may confer a hepatic glucocorticoid signaling environment less prone to GR-driven LDL elevation — potentially a more favorable metabolic set point maintained across decades. This remains speculative given the intronic location and absence of direct functional characterization.

The Evidence

All three rs2918418 findings emerge from a single cohort study. Olczak et al. (2019)⁴⁴ Olczak et al. (2019)
Glucocorticoid receptor (NR3C1) gene polymorphisms are associated with age and blood parameters in Polish Caucasian nonagenarians and centenarians. Exp Gerontol. 2019;116:20-24 genotyped three NR3C1 intronic variants in 552 long-lived subjects (ages 95–106) and 284 cord blood controls of Polish Caucasian ancestry.

For rs2918418, two statistically significant associations were reported: the CC genotype was more frequent in the long-lived cohort (p = 0.028), and the GG genotype was specifically associated with elevated total cholesterol (p = 0.03) and LDL cholesterol (p = 0.03) within the centenarian population. The longevity association (p = 0.028) is the weakest of the three NR3C1 variants studied — rs2963154 showed p = 0.002 for TT enrichment and rs10515522 showed p = 0.016 for TT enrichment. Importantly, rs2918418 is the only one of the three variants where the rare homozygote, rather than the common genotype, shows the longevity enrichment.

The LDL finding is particularly actionable: unlike HDL, which has complex and context-dependent cardiovascular consequences at elevated levels, elevated LDL is a well-established independent cardiovascular risk factor. The GG genotype's association with both elevated total cholesterol and LDL in an elderly cohort who have survived to extreme age suggests this genotype imposes a lipid-metabolism burden that persists even in robust long-term survivors.

No independent replication of this specific variant's longevity or cholesterol associations has been published. The variant does not appear in GWAS catalog hits for lipid traits or longevity phenotypes in larger European cohorts, consistent with a modest or population-specific effect. The evidence level is emerging.

Practical Implications

For the majority of people carrying the GG genotype, the association with elevated LDL and total cholesterol in the oldest-old argues for proactive lipid monitoring — not as a response to current disease, but as a mechanism to detect GR-driven hepatic cholesterol dysregulation before it accumulates cardiovascular risk over decades. The GR-to-PCSK9 pathway is pharmacologically relevant: if LDL elevation is detected and partially driven by altered NR3C1 hepatic signaling, PCSK9 inhibitors (evolocumab, alirocumab) target the mechanism more precisely than dietary LDL reduction alone.

For the rare CC carriers, no longevity intervention is warranted — the CC enrichment in centenarians reflects a favorable metabolic background, not a pharmacological target. The practical value is contextual: CC status provides reassurance that this particular NR3C1 locus is not contributing to GR-driven LDL elevation.

Interactions

rs2918418 operates in the same gene as three other NR3C1 variants in the GeneOps database: rs6198 (9β)⁵⁵ rs6198 (9β), which favors the glucocorticoid-resistant GRβ isoform and blunts cortisol response; rs41423247 (BclI)⁶⁶ rs41423247 (BclI), which increases GR sensitivity to glucocorticoids; and rs2963154⁷⁷ rs2963154, whose TT genotype is the strongest longevity signal in the same cohort.

The three longevity variants (rs2918418, rs2963154, rs10515522) were studied together in the same population and may partially tag overlapping regulatory haplotypes within the NR3C1 intron. A person carrying GG at rs2918418, CC at rs2963154 (elevated cholesterol + depleted from centenarians), and TT at rs10515522 (no survival benefit) would accumulate a full unfavorable NR3C1 longevity profile — a combination that warrants cholesterol surveillance regardless of which individual variant drives the effect.

The WNT16 gene encodes a signaling protein¹¹ signaling protein
WNT16 is a member of the Wingless-related integration site (WNT) family of secreted glycoproteins that regulate bone homeostasis crucial for bone development and maintenance. Among all the WNT family members, WNT16 stands out for its specific and powerful effect on cortical bone — the dense outer layer of bone that provides structural strength and accounts for about 80% of the skeleton's mass. The rs3801387 variant lies in the last intron of WNT16 and is part of a regulatory region²² regulatory region
The variant is in high linkage disequilibrium with other functional variants including eQTLs that affect WNT16 and neighboring gene expression that influences how much WNT16 protein your bone cells produce.

The Mechanism

WNT16 is primarily expressed by osteoblasts³³ primarily expressed by osteoblasts
bone-forming cells lining the cortical bone surface, where it plays a dual role in maintaining bone strength. First, it acts directly on osteoclast precursors to inhibit their differentiation into bone-resorbing osteoclasts through a non-canonical signaling pathway. Second, it increases expression of osteoprotegerin (OPG) in osteoblasts, which acts as a decoy receptor for RANKL, further suppressing osteoclastogenesis. The net result is reduced bone resorption on the inner (endocortical) surface, preserving cortical thickness.

The rs3801387 variant affects this system through regulatory mechanisms. The A allele is associated with lower bone mineral density⁴⁴ A allele is associated with lower bone mineral density, while the G allele appears protective, correlating with higher BMD and thicker cortical bone. In a region of high linkage disequilibrium spanning WNT16 and the adjacent FAM3C gene, rs3801387 tags multiple functional variants that influence gene expression. This makes rs3801387 a reliable proxy for overall WNT16 function, which is why it has emerged as the sentinel SNP in multiple GWAS⁵⁵ sentinel SNP in multiple GWAS for bone traits.

The Evidence

Multiple large-scale studies have established rs3801387's role in bone health. A GWAS meta-analysis of cortical bone thickness in 5,878 individuals⁶⁶ GWAS meta-analysis of cortical bone thickness in 5,878 individuals identified WNT16 variants associated with both cortical thickness and forearm BMD at genome-wide significance (P = 6.2×10⁻⁹ for cortical thickness). The study also demonstrated association with forearm fracture risk (OR = 1.33 for fractures, P = 7.3×10⁻⁹). A meta-analysis restricted to premenopausal women (n=4,061)⁷⁷ meta-analysis restricted to premenopausal women (n=4,061) found rs3801387 reached genome-wide significance for lumbar spine BMD (P = 1.7×10⁻⁹ in discovery, improving to P = 1.3×10⁻¹¹ in joint analysis). Each copy of the minor G allele was associated with approximately 0.16 SD higher BMD, explaining 0.6-1.8% of BMD variance.

Functional validation came from Wnt16 knockout mice⁸⁸ Wnt16 knockout mice, which developed spontaneous fractures due to 27% thinner cortical bone and high cortical porosity. Bone strength was reduced by 43-61% at both femur and tibia. Critically, trabecular (spongy) bone was unaffected, confirming WNT16's cortical-specific role. The effect persists through the lifespan — conditional inactivation in adult mice⁹⁹ conditional inactivation in adult mice showed that WNT16 continues to regulate cortical thickness even after peak bone mass is achieved, suggesting interventions targeting this pathway could benefit older adults.

Interestingly, the effect of rs3801387 may interact with mechanical loading. A study of male endurance runners¹⁰¹⁰ male endurance runners found AA genotype runners had 14% lower lumbar spine BMD than AA genotype non-athletes (P < 0.001), while AG+GG genotype runners actually had 5% higher leg BMD than non-athletes. This suggests that in individuals with lower baseline WNT16 function (AA genotype), the repetitive loading of endurance running may not adequately compensate for reduced WNT16-mediated osteoclast suppression.

Practical Implications

Your genotype at rs3801387 provides insight into your cortical bone health trajectory, particularly your risk of non-vertebral fractures — those occurring at the hip, wrist, and other sites rich in cortical bone. Non-vertebral fractures cause enormous disability and mortality in older adults, yet existing osteoporosis treatments have only marginally reduced their incidence compared to the dramatic reductions seen for vertebral fractures. Understanding your genetic predisposition allows for earlier and more targeted preventive measures.

If you carry the AA genotype (higher risk), optimizing peak bone mass in early adulthood and minimizing bone loss thereafter becomes especially important. This means ensuring adequate calcium (1,000-1,200 mg/day) and vitamin D (800-1,000 IU/day for adults over 50) throughout life. Weight-bearing exercise ¹¹¹¹ Weight-bearing exercise is the single best intervention for cortical bone, as mechanical loading stimulates periosteal (outer surface) bone formation. For AA individuals who participate in high-volume endurance exercise, monitoring bone density and potentially incorporating resistance training may be particularly important.

Because WNT16 specifically affects cortical bone, standard DEXA scans of the hip and forearm (cortical-rich sites) are more informative than lumbar spine scans for monitoring your bone health trajectory. Consider establishing a baseline BMD measurement in your 40s if you have the AA genotype and additional risk factors (family history, low body weight, smoking, glucocorticoid use).

Interactions

Rs3801387 is in high linkage disequilibrium with other WNT16 variants including two missense SNPs (rs2707466 Thr>Ile and rs2908004 Gly>Arg) and rs7776725 in the adjacent FAM3C gene. These variants form haplotype blocks where the minor alleles generally cluster together and have a protective effect on BMD. When assessing bone health risk, consider that these variants act as a functional unit rather than independent factors.

WNT16 is part of the broader WNT signaling pathway, which includes other bone-related genes identified in GWAS such as LRP5, SOST, DKK1, and RANKL. However, WNT16's effect is uniquely cortical-specific, distinguishing it from pathway members that affect trabecular bone. This suggests that individuals with risk variants in both WNT16 and trabecular-affecting genes (like SOST) may face compounded fracture risk across multiple skeletal sites.

The interaction between rs3801387 genotype and vitamin D status deserves attention. A study in adolescents found multi-locus interactions between WNT16 rs3801387, vitamin D receptor (VDR), and vitamin D binding protein (VDBP) variants affecting serum vitamin D levels and bone quality ¹²¹² multi-locus interactions between WNT16 rs3801387, vitamin D receptor (VDR), and vitamin D binding protein (VDBP) variants affecting serum vitamin D levels and bone quality . While this finding needs replication, it suggests that individuals with the AA genotype may derive particular benefit from maintaining optimal vitamin D status, as the two systems appear to interact in regulating bone homeostasis.

Your heart muscle is held together by molecular anchors called desmosomes¹¹ desmosomes
protein complexes at the intercalated discs between cardiomyocytes — they transmit mechanical force and maintain cell-cell adhesion during every heartbeat. Desmoplakin (DSP) is the largest desmosomal protein and acts as the structural linchpin, connecting desmosomal cadherins at the cell surface to the intermediate filament cytoskeleton deep inside the cell. Without functional desmoplakin, cardiac cells cannot hold together under the mechanical stress of beating, leading to cell death, fibrofatty replacement of the myocardium, and the substrate for life-threatening arrhythmias.

The p.Arg160Ter mutation (c.478C>T, NM_004415.4) converts arginine at position 160 into a premature stop codon. The resulting truncated mRNA is targeted for nonsense-mediated decay²² nonsense-mediated decay
a cellular quality-control mechanism that degrades mRNA transcripts containing premature stop codons, preventing production of toxic truncated proteins — meaning the mutant allele produces essentially no functional desmoplakin protein. The result is haploinsufficiency: only one functional DSP allele remains to supply desmoplakin to every intercalated disc in every cardiomyocyte, leaving the heart structurally vulnerable.

This variant is classified Pathogenic/Likely pathogenic by 10 major genetic testing laboratories in ClinVar (VCV000044922), including GeneDx, Mayo Clinic Laboratories, Ambry Genetics, Labcorp Genetics, and the Stanford Center for Inherited Cardiovascular Disease — the highest possible evidence tier for rare disease variants.

The Mechanism

The p.Arg160Ter variant sits in the N-terminal head domain of DSP, upstream of the plakin domain and both spectrin repeat rod domains. A stop codon this early in the protein eliminates the entire functional architecture of desmoplakin. Recent experimental work³³ Recent experimental work
Smith et al., bioRxiv 2025 demonstrated that truncating DSP variants reduce DSP protein levels by 23–62% of normal in patient-derived cardiomyocytes. Under conditions of heightened contractile stress (simulated by endothelin-1 exposure), DSP-haploinsufficient cardiomyocytes showed 75% adhesion failure versus only 8% in controls. At baseline contractile load, adhesion was intact — explaining why carriers can appear clinically normal for decades before disease manifests during physiological or pathological stress (intense exercise, myocarditis, pregnancy).

The loss of desmosomal integrity triggers a cascade: cardiomyocytes detach and die, the immune system responds with inflammation, and myofibroblasts replace the lost muscle with fibrous and fatty tissue. This fibrofatty replacement creates late gadolinium enhancement⁴⁴ late gadolinium enhancement
a signal on cardiac MRI that indicates fibrous scar tissue, where gadolinium contrast agent persists because normal cardiomyocytes wash it out but scar tissue cannot visible on cardiac MRI and provides the electrical substrate for reentrant ventricular tachycardia and ventricular fibrillation.

The Evidence

DSP cardiomyopathy is now recognized as a distinct entity from classical arrhythmogenic right ventricular cardiomyopathy (ARVC). The landmark multicenter study by Smith et al., Circulation 2020⁵⁵ multicenter study by Smith et al., Circulation 2020
107 DSP and 81 PKP2 patients established that DSP mutations produce left-dominant disease in 55% of patients (versus 0% for PKP2), with LV late gadolinium enhancement in 40% and acute myocardial injury episodes — a myocarditis-like inflammatory flare — in 15%. Right ventricular cardiomyopathy was present in only 14% of DSP patients, meaning classical ARVC diagnostic criteria systematically miss DSP disease.

The largest outcomes study to date, Gasperetti et al., Eur Heart J 2025⁶⁶ Gasperetti et al., Eur Heart J 2025
800 patients with pathogenic DSP variants across 26 international institutions, found that 17.4% of DSP carriers experienced sustained ventricular arrhythmias (3.9%/year). Myocardial injury episodes — which 8.8% of carriers experienced — dramatically amplified subsequent risk: hazard ratio 2.394 for sustained VA and 5.064 for heart failure hospitalization.

For variants specifically triggering nonsense-mediated decay of both major DSP isoforms⁷⁷ nonsense-mediated decay of both major DSP isoforms
both DSP-I (ubiquitous isoform) and DSP-II (heart-enriched shorter isoform) are eliminated, maximizing the desmoplakin deficit in cardiac tissue — as p.Arg160Ter does — the Hoorntje et al., Circ Genom Precis Med 2023⁸⁸ Hoorntje et al., Circ Genom Precis Med 2023
170 DSP patients from an international cohort study found these individuals were dramatically overrepresented among clinically affected patients versus unaffected carriers (83.6% vs 16.4%, p<0.0001). Ventricular arrhythmia occurred in 33% of affected individuals in this cohort.

Genotype-phenotype analysis confirms that DSP non-missense variants (truncating, frameshift, splice site — all producing haploinsufficiency) carry substantially worse LV involvement than missense variants: LV dysfunction in 76.5% vs 10%⁹⁹ LV dysfunction in 76.5% vs 10% (p=0.001) and LV MRI involvement in 92% vs 22% (p=0.001).

Practical Actions

Carriers of pathogenic DSP variants require cardiomyopathy-specialist care, not routine cardiology follow-up. The standard ARVC Task Force Criteria are specifically less sensitive for DSP disease because they prioritize right ventricular findings — a cardiac MRI protocol looking for subepicardial LV late gadolinium enhancement is the key diagnostic test.

Risk stratification now has a validated clinical tool: the DSP risk score integrates female sex, NSVT history, PVC burden, LVEF, and RV function to stratify 5-year VA risk as low (<5%), intermediate (5–20%), or high (>20%). Patients in the high-risk category should be considered for ICD implantation regardless of whether they have had a documented arrhythmic event. Patients who experience a myocardial injury episode (acute troponin rise with myocarditis- like presentation) should be urgently re-evaluated, as this dramatically escalates risk.

First-degree family members (parents, siblings, children) each carry a 50% risk of inheriting this variant. Cascade genetic testing and cardiac imaging of all adult relatives is standard of care.

Interactions

The R160* variant eliminates both major DSP isoforms (DSP-I and DSP-II) through nonsense-mediated decay — this biallelic isoform impact distinguishes early-truncating variants from variants that spare the heart-enriched DSP-II isoform and may explain the particularly high clinical penetrance observed.

DSP haploinsufficiency can interact with physiological demands that stress desmosomal integrity: intense endurance or resistance exercise, viral myocarditis, and pregnancy have all been associated with acute myocardial injury episodes (inflammatory flares) in DSP cardiomyopathy carriers. These events — detectable by troponin elevation — independently predict subsequent arrhythmia and heart failure and should prompt immediate cardiac evaluation.

Among desmosomal gene variants, double-variant carriers (a pathogenic DSP variant plus a pathogenic variant in PKP2, DSG2, or DSC2) show substantially worse outcomes than single-variant carriers in the desmosomal cardiomyopathy cohort data. If additional desmosomal variants are identified on clinical genetic testing, this escalates management urgency.

Every time your body encounters a bacterium, a first-responder system fires before the adaptive immune response even wakes up. Toll-Like Receptor 2 (TLR2)¹¹ Toll-Like Receptor 2 (TLR2)
TLR2 is a pattern-recognition receptor on the surface of macrophages, monocytes, dendritic cells, and epithelial cells stands at this front line, recognizing bacterial lipoproteins, peptidoglycan, lipoteichoic acid, and mycobacterial components. The R753Q variant (rs5743708), caused by a G-to-A transition at nucleotide 2258, replaces the positively charged arginine with neutral glutamine at position 753 in the receptor's TIR domain²² TIR domain
the Toll/IL-1 receptor domain — the intracellular signaling region that recruits adaptor proteins and initiates the inflammatory cascade. This single amino acid swap disables much of TLR2's capacity to fire.

The R753Q variant is almost exclusively a European polymorphism: approximately 3% of people of European descent carry at least one copy, compared to less than 0.3% in African and East Asian populations. This population specificity makes it a particularly important variant for European-ancestry users.

The Mechanism

The substitution of glutamine for arginine at position 753 changes the electrostatic potential of the DD loop³³ electrostatic potential of the DD loop
a structural element in the TIR domain critical for protein-protein interactions — the precise region where adaptor proteins dock onto TLR2. The consequences cascade through the entire signaling chain: R753Q TLR2 exhibits severely impaired tyrosine phosphorylation⁴⁴ severely impaired tyrosine phosphorylation
4.8-7.5-fold reduction compared to wild-type — a proximal step required for signaling complex assembly, fails to efficiently dimerize with its partner TLR6 (5.9-8-fold reduction), and blocks recruitment of the adaptor proteins MAL and MyD88 that relay the signal to NF-κB.

The end result: where wild-type TLR2 produces 42-fold induction of IL-8 in response to inactivated Mycobacterium tuberculosis components, R753Q TLR2 produces only 4-fold induction⁵⁵ 4-fold induction
even a 100-fold increase in mutant TLR2 expression cannot overcome this deficit. The defect is qualitative, not merely quantitative — the receptor is functionally crippled regardless of how much of it is present. Studies using knock-in mice confirmed that macrophages expressing R753Q show reduced TNF-α, IL-1β, IL-6, and IL-10 production⁶⁶ reduced TNF-α, IL-1β, IL-6, and IL-10 production
along with impaired IRAK-1, p38, ERK1/2, and NF-κB p65 phosphorylation upon mycobacterial challenge.

The Evidence

Tuberculosis is the most extensively studied consequence. A meta-analysis of 19 case-control studies⁷⁷ meta-analysis of 19 case-control studies
4,970 tuberculosis cases and 4,105 controls from Asian and Caucasian populations found that the A allele confers an odds ratio of 2.80 for tuberculosis disease across all genetic models, rising to 5.80 for AA homozygotes. The risk is consistent across both Asian and Caucasian populations, though slightly higher in Asians (OR 3.42 vs 2.39 in Caucasians in the allelic model).

CMV after transplantation shows the most dramatic individual finding. A study of 737 liver transplant recipients⁸⁸ 737 liver transplant recipients
92 patients (12.5%) developed CMV disease within 24 months found that homozygosity for R753Q was associated with a hazard ratio of 3.41 for tissue-invasive CMV disease. This reflects TLR2's documented role in recognizing CMV glycoprotein B — cells expressing R753Q TLR2 show abrogated NF-κB activity when challenged with CMV⁹⁹ abrogated NF-κB activity when challenged with CMV
validating the clinical transplant findings with functional data.

Atopic dermatitis with a severe phenotype clusters in R753Q carriers. The polymorphism defines a distinct subgroup¹⁰¹⁰ defines a distinct subgroup
9 of 78 AD patients (11.5%) were heterozygous for R753Q with median SCORAD scores of 55.8 vs 44.8 in non-carriers, and all carriers had SCORAD above 30 — indicating at least moderate disease. All carriers showed higher total IgE and Dermatophagoides pteronyssinus-specific IgE. A subsequent meta-analysis of nine studies¹¹¹¹ meta-analysis of nine studies
OR 2.07 for atopic dermatitis risk in Caucasians with GA genotype confirmed this association. The mechanism links to impaired IL-8 secretion in response to S. aureus¹²¹² impaired IL-8 secretion in response to S. aureus
which colonizes the skin of nearly all severe AD patients and perpetuates the inflammatory cycle.

Sepsis susceptibility is also elevated. A study using both computational structural modeling and patient data found significant association between TLR2 Arg753Gln and sepsis¹³¹³ significant association between TLR2 Arg753Gln and sepsis
under the over-dominant model, p=0.043, consistent with the expected biology of reduced inflammatory signaling impairing bacterial clearance.

Practical Implications

The picture painted across all these studies is consistent: R753Q carriers mount a blunted initial response when TLR2 ligands are present. This matters most for gram-positive bacteria (which produce the peptidoglycan and lipoproteins TLR2 recognizes), mycobacteria, and certain viruses like CMV. The implications are practical: faster medical attention for infections, optimizing vaccination status, and — for those with atopic dermatitis — recognizing that S. aureus colonization management is especially important.

Lyme disease is a notable exception. Patients with R753Q show significantly lower frequency in severe late-stage Lyme disease¹⁴¹⁴ significantly lower frequency in severe late-stage Lyme disease
possibly due to reduced inflammatory pathology from attenuated TLR2 responses to Borrelia spirochetes, suggesting the dampened immune response can be protective when the disease is primarily driven by immune overactivation rather than pathogen burden.

Interactions

TLR2 does not act alone. It forms heterodimers with TLR1 (recognizing triacylated lipopeptides) and TLR6 (recognizing diacylated lipopeptides and lipoteichoic acid) — and R753Q directly impairs this dimerization. TLR1 rs5743618, a common coding variant, alters TLR1 surface expression and affects combined TLR1/TLR2 signaling; the CGG haplotype (rs5743618–rs5743708–rs5743810 in TLR6) was associated with increased leprosy susceptibility in a Colombian population, suggesting additive effects across the TLR1/2/6 recognition complex.

The CD14 gene (rs2569190)¹⁵¹⁵ CD14 gene (rs2569190)
CD14 encodes the co-receptor that presents bacterial lipopolysaccharide and lipoproteins to TLR2 and TLR4 encodes a co-receptor that delivers bacterial products to TLR2 and TLR4. CD14 variants that reduce its expression would compound TLR2 R753Q impairment, potentially amplifying the signaling deficit further.

For individuals with TLR2 R753Q who also carry TLR4 Asp299Gly (rs4986790), the innate immune system faces a double impairment: blunted gram-positive and mycobacterial recognition (TLR2) alongside reduced gram-negative endotoxin recognition (TLR4). This combined state would warrant heightened infection awareness across a wider pathogen spectrum.

Your liver clears cholesterol from the bloodstream using a receptor called SR-BI, encoded by the SCARB1 gene. SR-BI is the primary docking site where HDL particles offload their cholesterol cargo for processing and excretion in bile — the final step of reverse cholesterol transport¹¹ reverse cholesterol transport
the process by which cholesterol is shuttled from peripheral tissues back to the liver for elimination. When SR-BI expression is reduced, HDL particles circulate longer without fully unloading their cargo, which can impair the liver's ability to process cholesterol and may subtly raise cardiovascular risk.

The rs5888 variant is a synonymous change in exon 8 of SCARB1 — synonymous meaning the amino acid sequence of the protein is unchanged. Yet the variant still matters: not every nucleotide change that preserves an amino acid is functionally neutral.

The Mechanism

Despite producing the same alanine amino acid (Ala350Ala), rs5888 alters the RNA secondary structure of the SCARB1 transcript. The T allele (the A allele on the genomic plus strand) creates a different codon — GCC instead of GCT — that causes the ribosomal machinery to stall. A key in vitro study²² key in vitro study
Constantineau et al. A synonymous variant in scavenger receptor, class B, type I gene is associated with lower SR-BI protein expression and function. Atherosclerosis, 2010 showed that cells expressing the risk variant have significantly lower SR-BI protein levels (p<0.04) and markedly reduced capacity for HDL cholesterol ester uptake (p<0.00001). The transcript levels are identical between genotypes — the difference is purely translational, with more mRNA trapped in non-translating ribosomal pools.

SR-BI also transports dietary carotenoids — particularly lutein and zeaxanthin — to the retinal pigment epithelium, where they form the macular pigment that filters harmful blue light. Impaired SR-BI activity can reduce delivery of these protective pigments to the macula, which may explain the AMD association described below.

The Evidence

A meta-analysis of 12 studies totalling 12,147 subjects³³ meta-analysis of 12 studies totalling 12,147 subjects
Ye et al. Meta-analysis of the association between SCARB1 polymorphism and fasting blood lipid levels. Oncotarget, 2017 found that T-allele carriers (in plus-strand notation: A-allele carriers) had significantly higher HDL-C and lower triglycerides specifically in non-Asian men (SMD 0.15 for HDL-C; p≤0.001). A separate meta-analysis of 7 studies⁴⁴ meta-analysis of 7 studies
Ma et al. SCARB1 rs5888 gene polymorphisms in coronary heart disease: A systematic review and meta-analysis. Gene, 2018 (6,360 subjects) found the T allele associated with reduced coronary heart disease risk in males (OR 0.79; 95% CI 0.61–1.01).

The effects are sex-specific and age-dependent. A Lithuanian population study⁵⁵ A Lithuanian population study
Stanislovaitiene et al. SCARB1 single nucleotide polymorphism (rs5888) is associated with serum lipid profile and myocardial infarction in an age- and gender-dependent manner. Lipids Health Dis, 2013 of 2,439 subjects found that TT homozygous older males (65–74 years) had dramatically reduced MI risk (OR 0.24, 95% CI 0.10–0.56, p=0.001) and higher HDL levels. In young females (25–44 years), TT was associated with lower LDL-C. A smaller Amish cohort⁶⁶ smaller Amish cohort
Roberts et al. Variants in scavenger receptor class B type I gene are associated with HDL cholesterol levels in younger women. Hum Hered, 2007 similarly found rs5888 associated with higher HDL-C in women under 50 but not in older women.

A pharmacogenomics study⁷⁷ pharmacogenomics study
Wu et al. Sex-Specific Influence of the SCARB1 Rs5888 SNP on the Serum Lipid Response to Atorvastatin in Patients with Acute Coronary Syndrome. Pharmgenomics Pers Med, 2020 found that female ACS patients carrying the T allele had a greater reduction in LDL-C and ApoB after atorvastatin treatment, suggesting genotype-specific statin responsiveness in women.

AMD and Carotenoid Transport

A case-control study⁸⁸ case-control study
Zerbib et al. rs5888 variant of SCARB1 gene is a possible susceptibility factor for age-related macular degeneration. PLoS One, 2009 in French and North American cohorts found that heterozygotes (CT genotype, i.e. AG in plus-strand notation) had substantially elevated AMD risk (pooled OR 2.9, 95% CI 1.6–5.3) compared to CC homozygotes — specifically among subjects without CFH or ARMS2 risk variants. The proposed mechanism is impaired SR-BI-mediated delivery of lutein and zeaxanthin to the retinal pigment epithelium.

This AMD association has not been replicated in large GWAS studies, so it should be interpreted as an emerging finding rather than established science.

Practical Actions

For the AA genotype (TT on coding strand), which has the lowest estimated SR-BI expression, the most directly actionable steps are dietary: ensuring adequate intake of preformed lutein and zeaxanthin (since SR-BI mediates their retinal delivery) and monitoring HDL-C as a surrogate for reverse cholesterol transport efficiency. For women on statins, the rs5888 genotype may influence treatment response, warranting closer monitoring.

Interactions

The lipid effects of rs5888 interact with those of CETP (rs708272) and LIPC (rs1532085) — genes that also regulate HDL metabolism. Individuals carrying risk alleles at multiple HDL pathway loci may have compounded HDL impairment beyond what rs5888 predicts alone. APOE (rs429358) interacts through a different mechanism: APOE ε4 impairs LDL clearance, and combined APOE4 + reduced SR-BI function could produce both LDL elevation and HDL impairment, though formal interaction studies are limited.

Your circulating vitamin B12 is not simply a readout of how much B12 you eat — it is actively shaped by the proteins that carry B12 in your blood and determine how quickly it is cleared from circulation. The FUT2 gene encodes alpha-(1,2)-fucosyltransferase 2¹¹ alpha-(1,2)-fucosyltransferase 2
An enzyme that adds fucose sugar residues to glycan chains on cell surfaces and on secreted proteins, creating the H blood group antigen on mucosal surfaces and modifying the glycosylation of carrier proteins like haptocorrin, an enzyme that influences B12 metabolism through a specific post-translational modification of haptocorrin — the protein that binds most of the B12 in your blood. The Gly258Ser variant (rs602662) changes a glycine to a serine at amino acid position 258 of the FUT2 protein. People with the G allele (Gly258) carry a form of FUT2 that more actively fucosylates haptocorrin, leading to lower measured serum B12. People with two A alleles (Ser258) have altered enzyme activity, less fucosylation of haptocorrin, and paradoxically higher circulating B12 measurements. This variant is in strong linkage disequilibrium²² linkage disequilibrium
When two SNPs are inherited together so frequently that knowing one predicts the other — in this case r² = 0.76-0.92 in Europeans with rs601338 (the W143X nonsense mutation that determines classical secretor status), but represents an independent missense change with its own protein-level consequences on enzymatic activity.

The Mechanism

FUT2 fucosylates haptocorrin³³ haptocorrin
Also called transcobalamin I or R-binder — a heavily glycosylated protein synthesized mainly by salivary glands and gastric mucosa that binds B12 in the gut to protect it from acid degradation, then releases it in the small intestine. In the bloodstream, haptocorrin carries approximately 70-80% of total serum B12, adding fucose residues to its complex glycan chains. This fucosylation affects how haptocorrin is recognized and cleared by the liver. The asialoglycoprotein receptor⁴⁴ asialoglycoprotein receptor
A lectin receptor on hepatocytes that preferentially binds and internalizes glycoproteins bearing exposed galactose or N-acetylgalactosamine residues — residues that become exposed when the terminal sialic acid is removed. Fucosylation competes with sialylation on these glycan positions, altering which glycoforms predominate (ASGR) on liver cells is responsible for clearing haptocorrin from the bloodstream. The degree of fucosylation alters the rate of this hepatic clearance. In carriers of the G allele (Gly258, higher FUT2 activity), haptocorrin is more thoroughly fucosylated, shifts toward the TCIII glycoform, and is cleared more efficiently from the blood — resulting in lower measured serum B12. In AA individuals (Ser258, lower FUT2 activity on this residue), haptocorrin retains more sialylation, resists ASGR-mediated clearance, and accumulates to higher levels in the bloodstream. Critically, Velkova et al. 2017⁵⁵ Velkova et al. 2017
Velkova A et al. The FUT2 secretor variant p.Trp154Ter influences serum vitamin B12 concentration via holo-haptocorrin, but not holo-transcobalamin, and is associated with haptocorrin glycosylation. Hum Mol Genet, 2017 demonstrated that these FUT2 variants only affect holo-haptocorrin, not holo-transcobalamin⁶⁶ holo-transcobalamin
The approximately 20-30% of blood B12 bound to transcobalamin II — the only form actively taken up by cells via the TCN2 receptor. Only holoTC reflects the B12 available for cellular use; haptocorrin- bound B12 is not accessible to most cells — the biologically active fraction. This is the critical practical implication: standard serum B12 tests measure total B12 (mostly haptocorrin-bound), and GG individuals with lower total B12 may actually have normal cellular B12 availability, while standard tests can give an artificially low result. Conversely, AA individuals with higher total B12 measurements may have perfectly normal cellular B12 availability.

The Evidence

Two independent GWAS studies identified rs602662 as a top hit for plasma vitamin B12. Tanaka et al. 2009⁷⁷ Tanaka et al. 2009
Tanaka T et al. Genome-wide association study of vitamin B6, vitamin B12, folate, and homocysteine blood concentrations. Am J Hum Genet, 2009 analyzed 3,622 participants in three Italian cohorts and found rs602662 to be the single strongest genetic association with vitamin B12 (p = 2.83 x 10^-20). The combined analysis by Hazra et al. 2008⁸⁸ Hazra et al. 2008
Hazra A et al. Common variants of FUT2 are associated with plasma vitamin B12 levels. Nat Genet, 2008 in 2,717 women identified the FUT2 locus (lead SNP rs492602, in strong LD with rs602662) at p = 5.36 × 10⁻¹⁷, with GG individuals having substantially lower B12 than the AA group. A 2024 study in kidney transplant patients Kotowski et al.⁹⁹ Kotowski et al.
Kotowski M et al. The Importance of the FUT2 rs602662 Polymorphism in the Risk of Cardiovascular Complications in Patients after Kidney Transplantation. Int J Mol Sci, 2024 found that the G allele was present in 65% of hypertensive patients versus 56% of normotensive patients — consistent with the lower B12 leading to higher homocysteine and greater cardiovascular risk. A metabolic study de Luis et al. 2022¹⁰¹⁰ de Luis et al. 2022
de Luis DA et al. Effect of the variant rs602662 of FUT2 gene on anthropometric and metabolic parameters in a Caucasian obese population. Eur Rev Med Pharmacol Sci, 2022 found that AA homozygotes had significantly lower BMI, better lipid profiles, lower fasting glucose, reduced insulin resistance, and a 72% lower metabolic syndrome risk (OR 0.28) compared to GG+GA carriers — an observation that may connect FUT2 biology to wider metabolic regulation.

Practical Implications

The key practical point for GG individuals (and to a lesser extent GA carriers) is awareness: if your standard serum B12 test comes back in the lower-normal range, your result may be influenced by your genotype rather than your dietary intake alone. Requesting a holotranscobalamin¹¹¹¹ holotranscobalamin
Also called "active B12" or holoTC — the B12 fraction bound to transcobalamin II that is available for cellular uptake. Normal range is typically above 35-50 pmol/L test instead of, or alongside, total serum B12 gives a more accurate picture of your functional B12 status. Alternatively, methylmalonic acid (MMA) — which rises specifically when cells lack functional B12 — provides a direct functional readout. For AA individuals, the opposite consideration applies: your total serum B12 may read higher than average, but this primarily reflects haptocorrin-bound B12 in circulation, not improved cellular availability. Standard B12 testing can be misleadingly reassuring if cellular deficiency is a concern.

Interactions

rs602662 is in strong linkage disequilibrium with rs601338 (W143X, the primary European secretor variant) with r² = 0.76-0.92 in Europeans. Together these variants capture FUT2 enzymatic activity from two different positions in the protein — rs601338 causes complete truncation at Trp143, while rs602662 alters activity at Gly258. The associated B12-lowering effects of both variants are mediated through the same haptocorrin glycosylation mechanism, and their effects largely overlap in European populations. For individuals of East Asian ancestry, the classical W143X non-secretor allele (rs601338) is nearly absent. A different FUT2 variant, rs1047781 (A385T, Ile129Phe), is the primary East Asian non-secretor allele. The rs602662 Gly258Ser change is correspondingly rare in East Asian populations, making this variant much less informative in that ancestry context. The downstream effect of lower B12 from GG genotypes intersects with one-carbon metabolism. Vitamin B12 is required for the methionine synthase reaction that converts homocysteine back to methionine. Chronically lower B12 can raise homocysteine, increasing cardiovascular and neurological risk. This interaction is especially relevant in individuals who also carry MTHFR variants (rs1801133 C677T or rs1801131 A1298C) that impair folate-driven remethylation — the two pathways jointly determine homocysteine levels.

Monoamine oxidase A (MAOA) is a mitochondrial enzyme responsible for breaking down neurotransmitters including serotonin, dopamine, norepinephrine, and epinephrine¹¹ serotonin, dopamine, norepinephrine, and epinephrine
These are key chemical messengers that regulate mood, motivation, stress response, and emotional regulation. The rs6323 variant, despite being synonymous (meaning it doesn't change the amino acid sequence at position 297), significantly affects how efficiently this enzyme works. This is a classic example of how ²² DNA changes don't need to alter protein structure to have meaningful biological effects — they can influence gene expression, mRNA stability, or protein folding.

The variant exists in two forms: G, which produces higher MAOA activity, and T, which produces lower activity³³ G, which produces higher MAOA activity, and T, which produces lower activity
The G allele encodes the high-activity form while T encodes the low-activity form. Because MAOA is located on the X chromosome, males (who have only one X) express whichever version they inherit, while females (with two X chromosomes) can have varying combinations. About 29% of Europeans carry the T (lower activity) allele, with higher frequencies in East Asian populations (~48%).

The Mechanism

MAOA requires flavin adenine dinucleotide (FAD) as a covalently attached cofactor⁴⁴ flavin adenine dinucleotide (FAD) as a covalently attached cofactor
FAD is derived from riboflavin (vitamin B2) and is permanently bound to the MAOA enzyme. The R297R variant affects enzyme activity through mechanisms that remain incompletely understood but likely involve mRNA stability or protein folding efficiency rather than direct catalytic changes. Studies show the G allele is associated with 2-10 times higher MAOA expression compared to the T allele⁵⁵ Studies show the G allele is associated with 2-10 times higher MAOA expression compared to the T allele
This translates to faster breakdown of monoamine neurotransmitters.

Lower MAOA activity (T allele) leads to slower breakdown of serotonin, dopamine, and norepinephrine, resulting in higher baseline levels of these neurotransmitters. Conversely, higher activity (G allele) means faster degradation and potentially lower neurotransmitter availability, though the body often compensates through feedback mechanisms and altered receptor sensitivity⁶⁶ feedback mechanisms and altered receptor sensitivity
The relationship between MAOA activity and mood is complex and influenced by environmental factors.

The Evidence

The rs6323 variant has been extensively studied in psychiatric and behavioral contexts. A study of major depressive disorder found that patients with the highest-activity G or GG genotypes had significantly lower placebo response⁷⁷ A study of major depressive disorder found that patients with the highest-activity G or GG genotypes had significantly lower placebo response
PMID: 19593178. This suggests they may be less responsive to psychological interventions alone.

In Korean children, the TT genotype was protective against ADHD in girls with an odds ratio of 0.31⁸⁸ In Korean children, the TT genotype was protective against ADHD in girls with an odds ratio of 0.31
PMID: 29782859. Park et al., 2018. Journal of Korean Medical Science. However, results vary by sex and population, with some studies showing opposite effects in males versus females.

Research on aggression has linked the low-activity variants to increased impulsivity and reactive aggression, particularly in individuals who experienced childhood adversity⁹⁹ Research on aggression has linked the low-activity variants to increased impulsivity and reactive aggression, particularly in individuals who experienced childhood adversity
The gene-environment interaction is crucial — the variant alone doesn't determine behavior. The so-called "warrior gene" association has been sensationalized in media but represents a modest effect size in scientific studies¹⁰¹⁰ "warrior gene" association has been sensationalized in media but represents a modest effect size in scientific studies
The variant contributes to behavioral tendencies but doesn't determine outcomes.

Evidence level is strong based on consistent replication across multiple populations, though effect sizes are generally modest and highly context-dependent.

Practical Implications

For those with lower MAOA activity (T allele carriers), higher baseline neurotransmitter levels can manifest as emotional intensity, stress sensitivity, or difficulty with emotional regulation. Riboflavin is essential for MAOA function as the precursor to FAD¹¹¹¹ Riboflavin is essential for MAOA function as the precursor to FAD
Adequate B2 status supports optimal enzyme activity. Some individuals with slow MAOA variants report benefits from riboflavin supplementation (100-400 mg daily)¹²¹² riboflavin supplementation (100-400 mg daily)
This supports FAD synthesis and may help normalize enzyme activity.

MAOA activity naturally increases with age and in response to oxidative stress¹³¹³ MAOA activity naturally increases with age and in response to oxidative stress
This means someone with genetically low activity might find symptoms moderate over time. Higher activity variants (G allele) may benefit from ensuring adequate precursors for neurotransmitter synthesis.

For treatment response, antidepressant choice may be influenced by MAOA genotype, though this isn't yet standard clinical practice¹⁴¹⁴ antidepressant choice may be influenced by MAOA genotype, though this isn't yet standard clinical practice
SSRIs work by different mechanisms than MAO inhibitors and may have variable effectiveness. MAO inhibitors are typically reserved for treatment-resistant depression.

Interactions

rs6323 interacts with rs1137070, another functional MAOA variant¹⁵¹⁵ rs1137070, another functional MAOA variant
Together these define MAOA haplotypes with different activity levels. The uVNTR (variable number tandem repeat) in the MAOA promoter is perhaps the most well-known MAOA variant and works in combination with rs6323 to determine overall enzyme activity. Compound heterozygosity or multiple low-activity alleles across these variants can result in markedly reduced MAOA activity¹⁶¹⁶ Compound heterozygosity or multiple low-activity alleles across these variants can result in markedly reduced MAOA activity
This may increase susceptibility to mood and behavioral regulation challenges.

MAOA activity also influences the metabolism of tyramine, a dietary amine found in aged cheeses, fermented foods, and red wine¹⁷¹⁷ the metabolism of tyramine, a dietary amine found in aged cheeses, fermented foods, and red wine
Low MAOA activity can increase sensitivity to tyramine and risk of hypertensive reactions when combined with MAO-inhibiting medications.